A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes
Oral semaglutide (Rybelsus®) is a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-
1RA) with 94% homology to human GLP-1. It is the first GLP-1RA developed for oral …
1RA) with 94% homology to human GLP-1. It is the first GLP-1RA developed for oral …
A review on semaglutide: an oral glucagon-like peptide 1 receptor agonist in management of type 2 diabetes mellitus
S Kalra, R Sahay - Diabetes Therapy, 2020 - Springer
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of
glucose-lowering drugs. GLP-1 RAs can be classified according to their structure, duration of …
glucose-lowering drugs. GLP-1 RAs can be classified according to their structure, duration of …
Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
SA Brunton, O Mosenzon, EE Wright Jr - Postgraduate Medicine, 2020 - Taylor & Francis
Oral semaglutide is the first US Food and Drug Administration-approved oral glucagon-like
peptide-1 receptor agonist (GLP-1RA) for the treatment of type 2 diabetes (T2D). Prior …
peptide-1 receptor agonist (GLP-1RA) for the treatment of type 2 diabetes (T2D). Prior …
Efficacy and safety of oral semaglutide by baseline age in J apanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 J apan trials
A post‐hoc exploratory analysis of the PIONEER 9 and 10 trials evaluated the effect of
baseline age (< 65 and≥ 65 years) on the efficacy and safety of oral semaglutide in …
baseline age (< 65 and≥ 65 years) on the efficacy and safety of oral semaglutide in …
Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients
O Mosenzon, EM Miller, ML Warren - Postgraduate Medicine, 2020 - Taylor & Francis
Patients with type 2 diabetes (T2D) often have comorbidities, such as cardiovascular
disease or chronic kidney disease, and a large and growing proportion of the T2D patient …
disease or chronic kidney disease, and a large and growing proportion of the T2D patient …
[HTML][HTML] Пероральный семаглутид-новая¬ инновационная опция в терапии сахарного диабета 2 типа
МВ Шестакова, МШ Шамхалова, ГР Галстян… - Сахарный …, 2021 - cyberleninka.ru
Пероральный семаглутид-первый в классе агонистов рецепторов глюкагоноподобного
пептида-1, доступный в форме для приема внутрь. В рамках клинической программы …
пептида-1, доступный в форме для приема внутрь. В рамках клинической программы …
Oral semaglutide: the innovation in type 2 diabetes management
MV Shestakova, MS Shamkhalova… - Diabetes …, 2021 - dia-endojournals.ru
Oral semaglutide is the first-in-class glucagon-like peptide-1 receptor agonist available in
the form of pills administered per os. PIONEER—the clinical trial program assessing the …
the form of pills administered per os. PIONEER—the clinical trial program assessing the …
[PDF][PDF] Profile of People Initiating Oral Semaglutide for the Treatment of Type 2 Diabetes in Japan: Results of
K FUJIWARA, NJ BROGAARD, S LOPHAVEN… - shinryo-to-shinyaku.com
● Abstract Background: Oral semaglutide (Rybelsus®)-the first oral glucagon-like peptide 1
receptor agonist (GLP-1RA)‒has been approved for the treatment of type 2 diabetes (T2D) …
receptor agonist (GLP-1RA)‒has been approved for the treatment of type 2 diabetes (T2D) …